NASDAQ:KALVKalvista Pharmaceuticals Stock Price, Forecast & News

Kalvista Pharmaceuticals' stock was trading at $8.86 on March 11th, 2020 when Coronavirus reached pandemic status according to the World Health Organization (WHO). Since then, KALV shares have increased by 32.2% and is now trading at $11.71. View which stocks have been most impacted by Coronavirus.

3 Wall Street analysts have issued "buy," "hold," and "sell" ratings for Kalvista Pharmaceuticals in the last year. There are currently 3 buy ratings for the stock, resulting in a consensus recommendation of "Buy." View analyst ratings for Kalvista Pharmaceuticals.

Kalvista Pharmaceuticals is scheduled to release its next quarterly earnings announcement on Monday, July 20th 2020. View our earnings forecast for Kalvista Pharmaceuticals.

Kalvista Pharmaceuticals Inc (NASDAQ:KALV) released its quarterly earnings results on Tuesday, March, 10th. The specialty pharmaceutical company reported ($0.52) EPS for the quarter, missing the Zacks' consensus estimate of ($0.26) by $0.26. The specialty pharmaceutical company had revenue of $1.58 million for the quarter, compared to the consensus estimate of $3.30 million. Kalvista Pharmaceuticals had a negative return on equity of 32.17% and a negative net margin of 263.38%. View Kalvista Pharmaceuticals' earnings history.

3 analysts have issued 1-year target prices for Kalvista Pharmaceuticals' shares. Their forecasts range from $28.00 to $31.00. On average, they anticipate Kalvista Pharmaceuticals' stock price to reach $29.67 in the next twelve months. This suggests a possible upside of 153.3% from the stock's current price. View analysts' price targets for Kalvista Pharmaceuticals.

Press coverage about KALV stock has trended very negative recently, according to InfoTrie Sentiment. The research firm scores the sentiment of press coverage by reviewing more than six thousand blog and news sources. The firm ranks coverage of publicly-traded companies on a scale of negative five to five, with scores closest to five being the most favorable. Kalvista Pharmaceuticals earned a news impact score of -3.1 on InfoTrie's scale. They also assigned news coverage about the specialty pharmaceutical company a news buzz of 0.0 out of 10, meaning that recent press coverage is extremely unlikely to have an effect on the stock's share price in the next several days. View the latest news aboutKalvista Pharmaceuticals.

Kalvista Pharmaceuticals saw a decrease in short interest in April. As of April 30th, there was short interest totaling 359,200 shares, a decrease of 10.6% from the April 15th total of 401,600 shares. Based on an average daily volume of 140,400 shares, the days-to-cover ratio is currently 2.6 days. Approximately 2.9% of the shares of the stock are sold short. View Kalvista Pharmaceuticals' Current Options Chain.

Some companies that are related to Kalvista Pharmaceuticals include Rhythm Pharmaceuticals (RYTM), Gossamer Bio (GOSS), Stoke Therapeutics (STOK), ImmunoGen (IMGN), Omeros (OMER), Cue Biopharma (CUE), Nabriva Therapeutics (NBRV), Kala Pharmaceuticals (KALA), Kura Oncology (KURA), Cara Therapeutics (CARA), NextCure (NXTC), Homology Medicines (FIXX), Morphic (MORF), Provention Bio (PRVB) and Kadmon (KDMN). View all competitors.

Based on aggregate information from My MarketBeat watchlists, some companies that other Kalvista Pharmaceuticals investors own include Heron Therapeutics (HRTX), Sorrento Therapeutics (SRNE), Cara Therapeutics (CARA), Crispr Therapeutics (CRSP), Corbus Pharmaceuticals (CRBP), Agile Therapeutics (AGRX), GALAPAGOS NV/S (GLPG), Ritter Pharmaceuticals (RTTR), SCYNEXIS (SCYX) and Anavex Life Sciences (AVXL).

Kalvista Pharmaceuticals trades on the NASDAQ under the ticker symbol "KALV."

Kalvista Pharmaceuticals' stock is owned by a number of retail and institutional investors. Top institutional investors include Vivo Capital LLC (8.27%), Ikarian Capital LLC (5.30%), BlackRock Inc. (4.89%), Pictet Asset Management Ltd. (3.54%), Orbimed Advisors LLC (2.36%) and Ghost Tree Capital LLC (1.96%). Company insiders that own Kalvista Pharmaceuticals stock include Albert Cha, Andreas Maetzel, Benjamin L Palleiko, Christopher Yea, Daniel B Soland, Edward P Feener, Life Sciences Fund Iv (Gp) Sv, Svlsf Iv, Llc, Thomas Andrew Crockett and Venrock Healthcare Capital Par. View institutional ownership trends for Kalvista Pharmaceuticals.

KALV stock was sold by a variety of institutional investors in the last quarter, including Ghost Tree Capital LLC, International Biotechnology Trust PLC, Franklin Resources Inc., Squarepoint Ops LLC, WINTON GROUP Ltd, Wellington Management Group LLP, UBS Group AG, and Victory Capital Management Inc.. Company insiders that have sold Kalvista Pharmaceuticals company stock in the last year include Christopher Yea, Edward P Feener, and Thomas Andrew Crockett. View insider buying and selling activity for Kalvista Pharmaceuticals.

KALV stock was purchased by a variety of institutional investors in the last quarter, including Vivo Capital LLC, Ikarian Capital LLC, Orbimed Advisors LLC, DAFNA Capital Management LLC, Janus Henderson Group PLC, Sphera Funds Management LTD., JPMorgan Chase & Co., and Geode Capital Management LLC. Company insiders that have bought Kalvista Pharmaceuticals stock in the last two years include Albert Cha, and Daniel B Soland. View insider buying and selling activity for Kalvista Pharmaceuticals.

Shares of KALV can be purchased through any online brokerage account. Popular online brokerages with access to the U.S. stock market include Vanguard Brokerage Services, TD Ameritrade, E*TRADE, Robinhood, Fidelity, and Charles Schwab.

One share of KALV stock can currently be purchased for approximately $11.71.

Kalvista Pharmaceuticals has a market capitalization of $209.02 million and generates $16.13 million in revenue each year. The specialty pharmaceutical company earns $-20,820,000.00 in net income (profit) each year or ($1.38) on an earnings per share basis. Kalvista Pharmaceuticals employs 33 workers across the globe.

The official website for Kalvista Pharmaceuticals is www.kalvista.com.

Kalvista Pharmaceuticals' mailing address is 55 Cambridge Parkway Suite 901E, CAMBRIDGE MA, 02142. The specialty pharmaceutical company can be reached via phone at 857-999-0075 or via email at [email protected]